Sutro Biopharma presents positive data from trial for platinum-resistant ovarian cancer.

From GlobeNewswire: 2025-03-15 18:40:00

Sutro Biopharma announced encouraging data from the REFRαME-O1 trial with luveltamab tazevibulin for platinum-resistant ovarian cancer at the SGO Annual Meeting. The study showed improved response rates and safety profiles at an optimized dose of 5.2 mg/kg. Dr. Jung Yun Lee highlighted the potential for better patient responses, especially in those with FRα expression between 25% and 75% 2+. The presentation showcased an ORR of 32% for the 5.2 mg/kg group, with consistent activity across all FRα expression levels. Sutro is deprioritizing luvelta development but exploring out-licensing opportunities for unmet medical needs.



Read more at GlobeNewswire: Sutro Biopharma Presents Data from Dose-Optimization